Cargando…

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice

OBJECTIVE: HCV is a major cause of chronic liver disease worldwide, but the role of neutralising antibodies (nAbs) in its natural history remains poorly defined. We analysed the in vivo role of hypervariable region 1 (HVR1) for HCV virion properties, including nAb susceptibility. DESIGN: Analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prentoe, Jannick, Verhoye, Lieven, Velázquez Moctezuma, Rodrigo, Buysschaert, Caroline, Farhoudi, Ali, Wang, Richard, Alter, Harvey, Meuleman, Philip, Bukh, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136728/ https://www.ncbi.nlm.nih.gov/pubmed/26589670 http://dx.doi.org/10.1136/gutjnl-2015-310300

Ejemplares similares

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization
por: Pham, Long V., et al.
Publicado: (2022)

Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A
por: Velázquez-Moctezuma, Rodrigo, et al.
Publicado: (2017)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry
por: Prentoe, Jannick, et al.
Publicado: (2018)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
por: Yuan, Lunzhi, et al.
Publicado: (2019)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV
por: Mosa, Alexander I., et al.
Publicado: (2020)

An alternate conformation of HCV E2 neutralizing face as an additional vaccine target
por: Tzarum, Netanel, et al.
Publicado: (2020)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Economic study of the value of expanding HCV treatment capacity in Germany
por: Sbarigia, Urbano, et al.
Publicado: (2017)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
por: Fitzmaurice, Karen, et al.
Publicado: (2015)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1–7 in Infectious Cell Culture Systems
por: Scheel, Troels K. H., et al.
Publicado: (2012)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections
por: You, Hong, et al.
Publicado: (2015)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Remaining challenges in HCV elimination
por: Capraru, Camelia, et al.
Publicado: (2021)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
por: Van Renne, Nicolaas, et al.
Publicado: (2018)

In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus
por: Olesen, Christina Holmboe, et al.
Publicado: (2021)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers
por: Prentoe, Jannick, et al.
Publicado: (2022)

Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens
por: Prentoe, Jannick, et al.
Publicado: (2021)

Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination
por: Gupte, Gouri M, et al.
Publicado: (2012)

HvrBase++: a phylogenetic database for primate species
por: Kohl, Jochen, et al.
Publicado: (2006)

Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2015)

Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies
por: Velázquez-Moctezuma, Rodrigo, et al.
Publicado: (2021)

Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study
por: Lin, Ming-Shyan, et al.
Publicado: (2015)

Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study
por: Chang, Te-Sheng, et al.
Publicado: (2021)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study
por: De Toni, Enrico N, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4dbl3if4cqmj2mo6afmj157mkg